AscellaHealth Delivers Mid-Year Specialty Pharmacy Outlook to Help Payers Navigate Pipeline Innovation, Cost and Benefit Strategy
Globe Newswire • Thu Jul 30 2026
AscellaHealth announces the release of its Q2 2026 Specialty & Rare Pipeline Digest.
BERWYN, Pa., July 30, 2026 (GLOBE NEWSWIRE) – AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, today announces the release of its Q2 2026 Specialty & Rare Pipeline Digest, a strategic mid-year outlook on the specialty drug landscape, providing in-depth analysis of recent FDA approvals, regulatory decisions, late-stage pipeline developments and emerging market trends that are reshaping specialty pharmacy strategy for healthcare payers, employers, pharmacy benefit organizations and other benefit decision-makers.
To read more, click here
About AscellaHealth
Healthcare today is more complex than ever—especially when it comes to therapies for people living with rare and chronic conditions. These high-cost, high-impact treatments account for only a small fraction of prescriptions, but they make up the largest and fastest-growing share of total drug spend. As a result, balancing affordability and quality of care remains a significant challenge.
We’re here to change that.
Because at AscellaHealth, we believe that all patients in need should have the ability to access life-changing therapies.
Our Core Beliefs
At AscellaHealth, patients are not just part of the process—they’re why we do what we do. Every solution we build and every partnership we form is designed with the patient in mind.
Patients First, Always.
Balancing Cost and Care.
Better Stakeholder Outcomes.